⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Leptin (Nasal Spray)
Leptin in its nasal form is in the early research stage. Data on intranasal administration is very limited.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Mechanism of Action
Leptin signals satiety via receptors in the hypothalamus. Nasal administration could theoretically provide direct central access, but its large molecular weight (16 kDa) is a significant barrier.
Overview
- Early research stage
- Very limited nasal administration data
- The approved form is subcutaneous only (Myalept)
- No usage instructions are provided
Intranasal Delivery — Research Data
- Nasal Leptin is in a very early research stage.
- Minimal published data on intranasal administration in humans.
- The approved form (Metreleptin/Myalept) is administered only subcutaneously.
Limited evidence
Very few published data on intranasal delivery.
Dosing Table — Leptin Nasal Spray (Early Research)
| Period | Dose | Notes |
|---|---|---|
| Research | Not established | — |
Very limited research data. There is no established nasal dosing.
Formulation Notes
No self-preparation instructions provided
- No approved nasal formulation exists.
- Nasal bioavailability of large proteins (16 kDa) is generally very low.
Storage After Opening
- Research stage — no commercial formulations exist.
Dosing Protocol
- There is no established nasal administration protocol.
Storage Instructions
- Research stage.
Important Notes
- Nasal Leptin is in a very early research stage.
- Bioavailability via the nasal route for proteins of this size is very low.
- No usage instructions are provided.
Benefits & Side Effects
Potential Benefits
- Theoretical central action on satiety (research)
Potential Side Effects
- Unknown side effects of the nasal form (insufficient data)
References
Intranasal Peptide Delivery: Complete Guide
Bioavailability, absorption factors, comparison with injectables, and limitations of nasal delivery.
Research Limitations
The data on this page is strictly educational. No self-preparation or self-administration instructions are provided.
External Sources & Regulatory Status
Regulatory Approvals
Myalept® (metreleptin) · Generalised lipodystrophy (2014)
Myalepta® (metreleptin) · Lipodystrophy (2018)
FDA + EMA approved as metreleptin for generalised/partial lipodystrophy.
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →